##### 



Exhibit 10.40
 [..**..] = Certain
 Confidential Information Containedin this Document, Marked by Brackets, Has Been
Omitted and Filed Separately with the Securities
and Exchange Commission Pursuant to rule 24b-2
of the Securities Exchange Act of 1934, as Amended.
 Exhibit A-1
 LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT
 Agreement   Myogen rd NIBRI
 Collaboration Agreement
 Introduction
    [..**..] Confidential Treatment Requested
 1




---



##### 



ARTICLE I
 Definitions
 1.1. Active Compound
 1.2. Affiliate
 1.3. Cardiac Field
 1.4. Collaboration Agreement
 1.5. Collaboration Compound
 1.6. Collaboration Target
 1.7. Commencement Date
 1.8. Compound
 1.9. Controlled
 1.10. Co-Promotion Expenses
 [..**..] Confidential Treatment Requested
 2




---



##### 



(a)
 (b)
 (c)
 (d)
 (e)
 (f)
 (g)
 (h)
 (i)
 (j) provided however
 (k)
 [..**..] Confidential Treatment Requested
 3




---



##### 



(l)
  1.11. Co-Promotion Notice
 1.12. Co-Promotion Response
 1.13. Co-Promotion Share
 1.14. Development Candidate
 1.15. Development Costs provided
 [..**..] Confidential Treatment Requested
 4




---



##### 



(a)
 (b)
 (c)
 (d)
 (e)
 1.16. Development Program
 [..**..] Confidential Treatment Requested
 5




---



##### 



1.17. Drug Product
 1.18. European Co-Promotion Share [..**..] [..**..] [..**..]
 1.19. European Countries
 1.20. Expanded Cardiovascular Field
 1.21. Expiration Date
 [..**..] Confidential Treatment Requested
 6




---



##### 



1.22. First Commercial Sale
 1.23. GCP
 1.24. GLP
 1.25. GMP
 1.26. Gross Contribution [..**..]
 (a)
    
    [..**..]; and(b)
    
    [..**..].
 1.27. Improvement
 1.28. Improvement Patent
 [..**..] Confidential Treatment Requested
 7




---



##### 



1.29. IND
 1.30.  In Vivo Validation in vivo in vivo
 1.31. Joint Patent
 1.32. Joint Know-How
 1.33. Joint Technology
 1.34. Know-How
 [..**..] Confidential Treatment Requested
 8




---



##### 



1.35. Know-How Period
 1.36. Licensed Field
 1.37. Licensed Patents
 1.38. Listed Country
 1.39. Live Claim .
 1.40. Myogen Compound
 1.41. Myogen Know-How
 1.42. Myogen Patents
 1.43. Myogen Target
 1.44. Myogen Technology
 1.45. NDA
 [..**..] Confidential Treatment Requested
 9




---



##### 



1.46. Net Sales
 (a)
 (b)
 (c)
 (d)
 (e)
 (f)
 (g)
 (h)
 (i) [..**..]
 (j)
 [..**..] Confidential Treatment Requested
 10




---



##### 



provided that
 (i)
 (ii)
 (iii)
 1.47. NIBRI Compound
 1.48. NIBRI Know-How
 [..**..] Confidential Treatment Requested
 11




---



##### 



1.49. NIBRI Patents
 1.50. NIBRI Technology
 1.51. Patent Period
 1.52. Patents
 1.53. Person
 1.54. Phase I Clinical Trial
 1.55. Phase II Clinical Trial
 1.56. Phase III Clinical Trial
 1.57. Phase IV Clinical Trial
 [..**..] Confidential Treatment Requested
 12




---



##### 



1.58. Registration Filing
 1.59. Regulatory Approval
 1.60. Regulatory Expenses
 1.61. Technology
 1.62. Territory [..**..]
 1.63. Third Party
 ARTICLE II
 Rights and Licenses
 2.1. NIBRI Rights
 [..**..] Confidential Treatment Requested
 13




---



##### 



2.2. Scope of Exclusivity; Diligence; Development Responsibility.
 (a)
 (i)
 (ii)
 (b)
 [..**..] Confidential
 Treatment Requested
 14




---



##### 



(c)
 2.3. Joint Inventions and Joint Patents. Joint Inventions
 2.4. Inventions Necessary to the License.
 2.5. Diagnostic and Prognostic Products.
 2.6. Right of First Negotiation to Discontinued NIBRI Compounds.
 [..**..] Confidential Treatment Requested
 15




---



##### 



[..**..] [..**..]
 ARTICLE III
 Development and Commercialization
 3.1. Development and Commercialization Rights. .
 3.2. Information Transfer.
 [..**..] Confidential Treatment Requested
 16




---



##### 



3.3. Regulatory Approvals.
 3.4. Due Diligence.
 3.5. Co-Funding and Co-Promotion Option.
 (a)
 [..**..] Confidential Treatment Requested
 17




---



##### 



Co-Promotion Notice [..**..] Co-Promotion
Response Co-Promotion Share provided [..**..] [..**..]
 (b)
 [..**..] Confidential Treatment Requested
 18




---



##### 



provided however
 (c) Definitive
Agreement
 (i)
 (ii)
 [..**..] Confidential Treatment Requested
 19




---



##### 



(iii) [..**..] [..**..]
 (iv) Expense
Reimbursement [..**..] [..**..] [..**..]
 (v)
 (vi)
 (d)
 [..**..] Confidential Treatment Requested
 20




---



##### 



(e) [..**..]
 ARTICLE IV
 Milestone and Royalty Payments
 4.1. Milestone Payments.
 (a)
 (b) [..**..]
 [..**..] Confidential Treatment Requested
 21




---



##### 



MILESTONEDEVELOPMENTAL MILESTONE:
    
    PAYMENTPre-Clinical Milestones:
    
    Validation of high-throughput assays*
    
    [..**..]
    
    In vitrovalidation of lead compound*
    
    [..**..]
    
    In VivoValidation of lead compound or use
of the lead compound as a starting point for
medicinal chemistry and/or SAR exploration*
    
    [..**..]
    
    Completion of Tox/ADME screening and
preclinical candidate determination*
    
    [..**..]Clinical Milestones:
    
    IND filing
    
    [..**..]
    
    Initiation of Phase II clinical evaluation
    
    [..**..]
    
    Initiation of Phase III clinical studies
    
    [..**..]
    
    Regulatory filing in the U.S.
    
    [..**..]
    
    First regulatory filing in the E.U.
    
    [..**..]
    
    Regulatory Approval in the U.S.
    
    [..**..]
    
    First Regulatory Approval in the E.U.
    
    [..**..]
 
 *
    
    Criteria for determining the achievement of any Milestone have been established by the JSC and
distributed to the parties under separate cover. 4.2. Royalty Payments During the Patent Period. [..**..]
 [..**..] Confidential Treatment Requested
 22




---



##### 



[..**..] [..**..]
 4.3. Royalty Payments During a Know-How Period. [..**..] provided however
 4.4. Responsibility for Myogens Third Party Royalty Obligations.
 4.5. Reduced Royalty Obligations.
 (a) [..**..] provided that
 (b)
 [..**..] Confidential Treatment Requested
 23




---



##### 



[..**..]
 (c) [..**..] provided however [..**..]
 4.6. Certain Understandings Regarding Royalty Payments.
 ARTICLE V
 Reporting Obligations
 5.1. Development Reports.
 5.2. Sales Reports and Records.
 [..**..] Confidential Treatment Requested
 24




---



##### 



ARTICLE VI
 Confidentiality
 6.1. Undertaking. Receiving
Party Proprietary Party
 (a)
 [..**..] Confidential Treatment Requested
 25




---



##### 



(b)
 (c)
 6.2. Exceptions.
 (a)
 (b)
 (c)
 6.3.
 [..**..] Confidential Treatment Requested
 26




---



##### 



(a)
 (b)
 6.4. Publicity.
 6.5. Survival.
 ARTICLE VII
 Patents
 7.1. Preparation.
 [..**..] Confidential Treatment Requested
 27




---



##### 



7.2. Infringement.
 ARTICLE VIII
 Term and Termination
 8.1. Term. Patent Period
 [..**..] Confidential Treatment Requested
 28




---



##### 



Know-How Period Expiration Date
 8.2. Material Breach by NIBRI.
 8.3. Termination.
 8.4. Effect of Termination.
 [..**..] Confidential Treatment Requested
 29




---



##### 



ARTICLE IX
 Miscellaneous Provisions
 9.1. Governing Law, and Jurisdiction.
 9.2. No Warranty.
 [..**..] Confidential Treatment Requested
 30




---



##### 



9.3. Third Party Actions.
 (a)
 (b) provided that
 [..**..] Confidential Treatment Requested
 31




---



##### 



9.4. Force Majeure.
 9.5. Waiver.
 9.6. Severability.
 [..**..] Confidential Treatment Requested
 32




---



##### 



9.7. Government Acts.
 9.8. Government Approvals.
 9.9. Export Controls.
 9.10. Assignment. without except
 [..**..] Confidential Treatment Requested
 33




---



##### 



provided that [..**..]
 9.11. Counterparts.
 9.12. No Agency.
 9.13. Notice.
 [..**..] Confidential Treatment Requested
 34




---



##### 



rd
  rd
 9.14. Headings.
 9.15. Authority.
 9.16. Entire Agreement.
 [..**..] Confidential Treatment Requested
 35




---



##### 



MYOGEN, INC.By:Title:Date of Signature:NOVARTIS INSTITUTES FOR BIOMEDICALRESEARCH, INC.By:Title:Date of Signature:
 [..**..] Confidential Treatment Requested
 36




---



##### 



Schedule 1.38
 Listed Countries
  Albania AL
    
    Algeria DZ
    
    Antigua and Barbuda AGArgentina
    
    Armenia AM
    
    Australia AUAustria AT
    
    Azerbaijan AZ
    
    Barbados BBBelarus BY
    
    Belgium BE
    
    Belize BZBenin BJ
    
    Bosnia and Herzegovina BA
    
    Botswana BWBrazil BR
    
    Bulgaria BG
    
    Burkina Faso BFCameroon CM
    
    Canada CA
    
    Central African Republic CFChad TD
    
    Chile
    
    China CNColombia CO
    
    Congo CG
    
    Costa Rica CRCôte dIvoire CI
    
    Croatia HR
    
    Cuba CUCyprus CY
    
    Czech Republic CZ
    
    Democratic Peoples
Republic of Korea KPDenmark DK
    
    Dominica DM
    
    Ecuador ECEgypt EG
    
    Equatorial Guinea GQ
    
    Estonia EEFinland FI 2
    
    France FR
    
    Gabon GAGambia GM
    
    Georgia GE
    
    Germany DEGhana GH
    
    Greece GR
    
    Grenada GDGuinea GN
    
    Guinea-Bissau GW
    
    Hong KongHungary HU
    
    Iceland IS
    
    India INIndonesia ID
    
    Ireland IE
    
    Israel ILItaly IT
    
    Japan JP
    
    Kazakhstan KZ 1Kenya KE
    
    Kyrgyzstan KG
    
    Latvia LVLesotho LS
    
    Liberia LR
    
    Liechtenstein LILithuania LT
    
    Luxembourg LU
    
    Madagascar MGMalawi MW
    
    Malaysia
    
    Mali MLMauritania MR
    
    Mexico MX
    
    Monaco MCMongolia MN
    
    Morocco MA
    
    Mozambique MZNetherlands NL 4
    
    New Zealand NZ
    
    Nicaragua NINiger NE
    
    Norway NO
    
    Oman OMPakistan
    
    Papua New Guinea PG
    
    PeruPhilippines PH
    
    Poland PL
    
    Portugal PTRepublic of Korea KR
    
    Republic of Moldova MD
    
    Romania RORussian Federation RU
    
    Saint Lucia LC
    
    Saint Vincent and the
Grenadines VCSaudi Arabia
    
    Senegal SN
    
    Serbia and Montenegro CSSeychelles SC
    
    Sierra Leone SL
    
    Singapore SGSlovakia SK
    
    Slovenia SI
    
    South Africa ZASpain ES
    
    Sri Lanka LK
    
    Sudan SDSwaziland SZ
    
    Sweden SE
    
    Switzerland CHSyrian Arab Republic SY
    
    Taiwan
    
    Tajikistan TJThailand
    
    The former Yugoslav
Republic of Macedonia MK
    
    Togo TGTrinidad and Tobago TT
    
    Tunisia TN
    
    Turkey TRTurkmenistan TM
    
    Uganda UG
    
    Ukraine UAUnited Arab Emirates AE
    
    United Kingdom GB
    
    United Republic of
Tanzania TZUnited States of America US
    
    Uruguay
    
    Uzbekistan UZVenezuela
    
    Viet Nam VN
    
    Zambia ZMZimbabwe ZW
 [..**..] Confidential Treatment Requested




---



##### 



Schedule 1.42
 Myogen Patents
 Schedule 1.42 Myogen PatentsPATENTS
    
    Filing Date
    
    App. No.
    
    Country
    
    Pat. No.
    
    Issue Date
    
    Subject MatterMYOG:004-USD1
    
    4/25/2000
    
    09/558,472
    
    U.S.
    
    
    
    
    
    Alpha Myosin Heavy Chain Gene TherapyMYOG:004-USD2
    
    10/1/2001
    
    09/969,086
    
    U.S.
    
    7,049,066
    
    5/23/2006
    
    Alpha Myosin Heavy Chain Therapeutic/ScreeningMYOG:004-USD3
    
    2/25/2005
    
    11/067,502
    
    U.S.
    
    
    
    
    
    Alpha Myosin Heavy Chain TreatmentMYOG:004-WO
    
    1/30/1998
    
    PCT/US98/01983
    
    PCT
    
    
    
    
    
    Alpha Myosin Heavy ChainMYOG:004-CA
    
    7/29/1999
    
    2,278,465
    
    Canada
    
    
    
    
    
    Alpha Myosin Heavy ChainMYOG:004-EP
    
    7/30/1999
    
    98906089.2
    
    Europe
    
    
    
    
    
    Alpha Myosin Heavy ChainMYOG:004-JP
    
    7/30/1999
    
    10-533182
    
    Japan
    
    
    
    
    
    Alpha Myosin Heavy ChainMYOG:005-US
    
    4/1/1998
    
    09/053,293
    
    U.S.
    
    6,218,597
    
    4/17/2001
    
    Transgenic mice w/cardiac specific promotersMYOG:006-US
    
    9/26/1997
    
    08/938,105
    
    U.S.
    
    6,353,151
    
    3/5/2002
    
    Transgeneic alpha myosinMYOG:006-EP
    
    5/24/1999
    
    97943597.1
    
    Europe
    
    
    
    
    
    Alpha Myosin TransgenesMYOG:007-US
    
    5/26/1998
    
    09/047,755
    
    U.S.
    
    6,203,776
    
    3/20/2001
    
    Methods for identifying adrenergic receptorsMYOG:013-US
    
    6/19/1998
    
    09/100,497
    
    U.S.
    
    5,998,458
    
    12/7/1999
    
    Positive inotrope + beta adrenergic receptor antagonistMYOG:013-WO
    
    6/24/1998
    
    PCT/US98/13442
    
    PCT
    
    
    
    
    
    Positive inotrope + beta adrenergic receptor antagonistMYOG:013-AU
    
    1/6/2000
    
    81740/98
    
    Australia
    
    731,656
    
    7/19/2001
    
    Positive inotrope + beta adrenergic receptor antagonistMYOG:013-CA
    
    12/23/1999
    
    2,295,094
    
    Canada
    
    
    
    
    
    Positive inotrope + beta adrenergic receptor antagonistMYOG:013-EP
    
    1/25/2000
    
    198,931,687
    
    Europe
    
    
    
    
    
    Positive inotrope + beta adrenergic receptor antagonistMYOG:013-JP
    
    12/27/1999
    
    11-505056
    
    Japan
    
    
    
    
    
    Positive inotrope + beta adrenergic receptor antagonistMYOG:020-US
    
    10/15/1998
    
    09/173,798
    
    U.S.
    
    6,201,165
    
    3/13/2001
    
    CamKIIa, CaMKIV,p38,MKK6,anf,bnp,beta myosin transgenesMYOG:020-WO
    
    10/16/1998
    
    PCT/US98/21988
    
    PCT
    
    
    
    
    
    CamKIIa, CaMKIV,p38,MKK6,anf,bnp,beta myosin transgenesMYOG:020-AU
    
    4/16/2000
    
    10992/99
    
    Australia
    
    755428
    
    8/16/2002
    
    CamKIIa, CaMKIV,p38,MKK6,anf,bnp,beta myosin transgenesMYOG:020-CA
    
    4/16/2000
    
    2,315,244
    
    Canada
    
    
    
    
    
    CamKIIa, CaMKIV,p38,MKK6,anf,bnp,beta myosin transgenesMYOG:020-EP
    
    4/16/2000
    
    98953672.7
    
    Europe
    
    
    
    
    
    CamKIIa, CaMKIV,p38,MKK6,anf,bnp,beta myosin transgenesMYOG:020-JP
    
    4/16/2000
    
    2000-516026
    
    Japan
    
    
    
    
    
    CamKIIa, CaMKIV,p38,MKK6,anf,bnp,beta myosin transgenesMYOG:020-MX
    
    4/14/2000
    
    0003678
    
    Mexico
    
    
    
    
    
    CamKIIa, CaMKIV,p38,MKK6,anf,bnp,beta myosin transgenesMYOG:023-US
    
    10/15/1998
    
    09/173,795
    
    U.S.
    
    6,673,768
    
    1/6/2004
    
    Calcineurin TherapiesMYOG:024-US
    
    11/10/1999
    
    09/438,075
    
    U.S.
    
    6,372,957
    
    4/16/2002
    
    MEF2 methods of treatmentMYOG:024-USC1
    
    1/9/2002
    
    10/043,658
    
    U.S.
    
    
    
    
    
    MEF2 screening methodsMYOG:024-WO
    
    11/10/1999
    
    PCT/US99/26725
    
    PCT
    
    
    
    
    
    MEF2MYOG:024-CA
    
    5/7/2001
    
    2,350,086
    
    Canada
    
    
    
    
    
    MEF2MYOG:024-EP
    
    5/21/2001
    
    99971848.9
    
    Europe
    
    
    
    
    
    MEF2MYOG:024-JP
    
    5/10/2001
    
    2000-581187
    
    Japan
    
    
    
    
    
    MEF2MYOG:025-US
    
    10/15/1998
    
    09/173,799
    
    U.S.
    
    6,657,104
    
    12/2/2003
    
    Calcineurin transgenicsMYOG:026-US
    
    8/20/2000
    
    09/643,206
    
    U.S.
    
    6,632,628
    
    8/20/2000
    
    HDAC screening and treatmentMYOG:026-USD1
    
    8/20/2003
    
    10/637,403
    
    U.S.
    
    
    
    
    
    HDAC transgenicsMYOG:026-WO
    
    8/20/2000
    
    PCT/US00/22958
    
    PCT
    
    
    
    
    
    Class II HDACsMYOG:026-CA
    
    2/14/2002
    
    2,382,045
    
    Canada
    
    
    
    
    
    Class II HDACsMYOG:026-EP
    
    3/13/2002
    
    00955805.7
    
    Europe
    
    
    
    
    
    Class II HDACsMYOG:026-JP
    
    2/19/2002
    
    2001-518892
    
    Japan
    
    
    
    
    
    Class II HDACsMYOG:028-US
    
    7/18/2001
    
    09/908,988
    
    U.S.
    
    6,740,751
    
    5/25/2004
    
    Muscle Ring Finger Proteins (MURFS) Screening and TreatmentMYOG:028-USD1
    
    2/10/2004
    
    10/775,627
    
    U.S.
    
    7,005,512
    
    2/28/2006
    
    Muscle Ring Finger Proteins (MURFS) Screening and TreatmentMYOG:028-USD2
    
    2/10/2004
    
    10/775,649
    
    U.S.
    
    issue fee
    
    paid
    
    Muscle Ring Finger Proteins (MURFS)MYOG:029-US
    
    4/16/1998
    
    09/061,417
    
    U.S.
    
    
    
    
    
    NF-AT3 inhibitorsMYOG:029-WO
    
    10/16/1998
    
    PCT/US98/21845
    
    PCT
    
    
    
    
    
    NF-AT3 inhibitorsMYOG:029-AU
    
    10/15/1998
    
    98058/98
    
    Australia
    
    748334
    
    9/12/2002
    
    NF-AT3 inhibitorsMYOG:029-CA
    
    4/10/2000
    
    2,306,448
    
    Canada
    
    
    
    
    
    NF-AT3 inhibitorsMYOG:029-EP
    
    5/16/2000
    
    9895233.7
    
    Europe
    
    
    
    
    
    NF-AT3 inhibitorsMYOG:029-JP
    
    4/17/2000
    
    2000-516024
    
    Japan
    
    
    
    
    
    NF-AT3 inhibitors
 [..**..] Confidential Treatment Requested




---



##### 



Schedule 1.42 Myogen PatentsPATENTS
    
    Filing Date
    
    App. No.
    
    Country
    
    Pat. No.
    
    Issue Date
    
    Subject MatterMYOG:034-US
    
    9/26/2002
    
    10/256,221
    
    U.S.
    
    6,707,686
    
    3/16/2004
    
    HDAC InhibitorsMYOG:034-USC1
    
    3/16/2004
    
    10/801,985
    
    U.S.
    
    6,946,441
    
    9/20/2005
    
    Inhibiting HDACsMYOG:034-USC2
    
    7/26/2005
    
    11/190,074
    
    U.S.
    
    
    
    
    
    Inhibiting HDACsMYOG:034-USC3
    
    8/30/2005
    
    11/215,844
    
    U.S.
    
    
    
    
    
    Inhibiting HDACsMYOG:034-EP
    
    9/27/2001
    
    02/021678.8
    
    Europe
    
    1,297,851
    
    1/26/2005
    
    Inhibiting HDACsMYOG:034-EPD1
    
    1/25/2005
    
    5001443
    
    Europe
    
    
    
    
    
    Inhibiting HDACsMYOG:034-JP
    
    9/27/2001
    
    2002-284313
    
    Japan
    
    
    
    
    
    Inhibiting HDACsMYOG:035-US
    
    1/21/2003
    
    10/348,598
    
    U.S.
    
    
    
    
    
    Hypertrophic Cell LineMYOG:036-US
    
    2/13/2001
    
    09/782,953
    
    U.S.
    
    
    
    
    
    MCIPs screening, treatment, transgenics, antibodiesMYOG:036-WO
    
    2/13/2001
    
    PCT/US01/21662
    
    PCT
    
    
    
    
    
    MCIPs screening, treatment, transgenics, antibodiesMYOG:036-CA
    
    1/24/2003
    
    2,415,967
    
    Canada
    
    
    
    
    
    MCIPs screening, treatment, transgenics, antibodiesMYOG:036-EP
    
    2/5/2003
    
    1952568.2
    
    Europe
    
    
    
    
    
    MCIPs screening, treatment, transgenics, antibodiesMYOG:036-JP
    
    12/26/2002
    
    2002-509354
    
    Japan
    
    
    
    
    
    MCIPs screening, treatment, transgenics, antibodiesMYOG:037-US
    
    8/20/2003
    
    10/644,659
    
    U.S.
    
    
    
    
    
    STARS screening, treatment, transgenics, antibodiesMYOG:044-US
    
    5/21/2003
    
    10/848,820
    
    U.S.
    
    
    
    
    
    PKD (HDAC Kinase I)MYOG:044-WO
    
    5/21/2003
    
    PCT/US04/015715
    
    PCT
    
    
    
    
    
    PKD (HDAC Kinase I)MYOG:044-AU
    
    5/21/2003
    
    2004249114
    
    Australia
    
    
    
    
    
    PKD (HDAC Kinase I)MYOG:044-BR
    
    5/21/2003
    
    
    
    Brazil
    
    
    
    
    
    PKD (HDAC Kinase I)MYOG:044-CA
    
    5/21/2003
    
    
    
    Canada
    
    
    
    
    
    PKD (HDAC Kinase I)MYOG:044-CN
    
    5/21/2003
    
    
    
    China
    
    
    
    
    
    PKD (HDAC Kinase I)MYOG:044-EP
    
    5/21/2003
    
    
    
    Europe
    
    
    
    
    
    PKD (HDAC Kinase I)MYOG:044-IN
    
    5/21/2003
    
    
    
    India
    
    
    
    
    
    PKD (HDAC Kinase I)MYOG:044-JP
    
    5/21/2003
    
    
    
    Japan
    
    
    
    
    
    PKD (HDAC Kinase I)MYOG:044-MX
    
    5/21/2003
    
    
    
    Mexico
    
    
    
    
    
    PKD (HDAC Kinase I)MYOG:045-US
    
    11/3/2004
    
    10/980,612
    
    U.S.
    
    
    
    
    
    Alpha myocin modulating compound R enatiomerMYOG:045-WO
    
    11/3/2004
    
    PCT/US04/036569
    
    PCT
    
    
    
    
    
    Alpha myocin modulating compound R enatiomerMYOG:046-US
    
    11/3/2004
    
    10/980,605
    
    U.S.
    
    
    
    
    
    Alpha myocin modulating compound S enatiomerMYOG:046-US
    
    11/3/2004
    
    PCT/US04/036568
    
    PCT
    
    
    
    
    
    Alpha myocin modulating compound S enatiomerMYOG:047-US
    
    11/13/2004
    
    10/988,192
    
    U.S.
    
    
    
    
    
    TRP ChannelMYOG:047-WO
    
    11/13/2004
    
    PCT/US04/037858
    
    PCT
    
    
    
    
    
    TRP ChannelMYOG:048-US
    
    12/23/2004
    
    11/018,426
    
    U.S.
    
    
    
    
    
    5-HT2 receptorsMYOG:048-WO
    
    12/23/2004
    
    PCT/US04/042922
    
    PCT
    
    
    
    
    
    5-HT2 receptorsMYOG:049-US
    
    12/23/2004
    
    11/018,383
    
    U.S.
    
    
    
    
    
    5-HT2 receptor binding compoundsMYOG:049-WO
    
    12/23/2004
    
    PCT/US04/042921
    
    PCT
    
    
    
    
    
    5-HT2 receptor binding compoundsMYOG:050-US
    
    2/2/2005
    
    11/049,630
    
    U.S.
    
    
    
    
    
    PRK (HDAC kinase II)MYOG:050-WO
    
    2/2/2005
    
    PCT/US05/002808
    
    PCT
    
    
    
    
    
    PRK (HDAC kinase II)MYOG:054-US
    
    4/5/2005
    
    11/099,417
    
    U.S.
    
    
    
    
    
    Nuclear exportMYOG:054-WO
    
    4/5/2005
    
    PCT/US05/011264
    
    PCT
    
    
    
    
    
    Nuclear exportMYOG:057-WO
    
    9/19/2005
    
    PCT/US05/033461
    
    PCT
    
    
    
    
    
    P38 MCIPMYOG:058-US
    
    8/15/2005
    
    11/203,828
    
    U.S.
    
    
    
    
    
    KuMYOG:060-USP1
    
    7/13/2005
    
    60/699,189
    
    U.S.
    
    
    
    
    
    Proteasome inhibitorsMYOG:062-USP1
    
    11/18/2005
    
    60/737,952
    
    U.S.
    
    
    
    
    
    CAMKII/Calpain/HDACsUTSD:803-US
    
    5/30/2002
    
    10/159,971
    
    U.S.
    
    6,924,415
    
    8/2/2005
    
    MEK5USTD:803-USD1
    
    4/21/2005
    
    11/089,425
    
    U.S.
    
    
    
    
    
    MEK5UTSD:803-CA
    
    5/29/2002
    
    2,384,907
    
    Canada
    
    
    
    
    
    MEK5UTSD:803-JP
    
    11/22/2001
    
    2001-358595
    
    Japan
    
    
    
    
    
    MEK5USTD:1771-USP1
    
    5/3/2006
    
    not yet assigned
    
    U.S.
    
    
    
    
    
    CAMTA
 [..**..] Confidential Treatment Requested